Denali Therapeutics

DNLIleader

Denali Therapeutics is developing disease-modifying therapies for neurodegeneration (Parkinson's, ALS, Alzheimer's) using proprietary blood-brain-barrier crossing platform and LRRK2 biology.

⇄ Compare

Produk & Pendapatan

Pangsa Pendapatan Produk

Komposisi Pendapatan ($188M)

Data statis (memuat keuangan langsung…)

Collaboration Revenue (Biogen, Sanofi) (100%)

Komposisi segmen dan pelanggan utama

Detail produk

LRRK2 Inhibitors (Parkinson's)40%

DNL201/DNL151 — oral LRRK2 kinase inhibitors targeting genetic Parkinson's disease, partnered with Sanofi.

Enzyme Transport Vehicle (ETV)35%

Blood-brain-barrier crossing technology enabling CNS delivery of large-molecule enzymes — licensed to multiple partners.

ALS Programs (TDP-43, RIPK1)25%

First-in-class RIPK1 inhibitor and TDP-43 programs for ALS, in Phase II with AZ collaboration.

Hubungan Rantai Pasok

Mitra

Biogen Inc.

ALS program collaboration

Dampak: significant

Konteks makro dan pasar

헬스케어Berita sektor

메디케어 수가 압박 vs AI 진단 효율화 — 선별적 접근 필요

미국 헬스케어 지출 (2026E)

$4.8T

AI 진단 정확도 개선

+23% vs 기존

UNH 의료손해율

87.3%

약가 협상 대상 의약품

20종 (IRA)

Katalis mendatang

◆CMS 메디케어 최종 수가 발표 (2026.Q2)◆UNH/HUM/CVS Q1 실적 (2026.04)◆IRA 약가 협상 2차 품목 공개

Berita terkini

Memuat berita...

Analisis AI

Klik "Dapatkan Analisis AI" untuk analisis rantai pasok Denali Therapeutics.

Info Perusahaan

Kantor Pusat

South San Francisco, California, USA

Didirikan

2015

Karyawan

700

Situs Web

denalitherapeutics.com

Gambaran umum sektor — 헬스케어

Berita sektor